An Early Phase 1 interventional study of 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use in HPV Infection, sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair. Active, not recruiting at 1 site in United States. Open to female participants aged 24 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-05-20.
Sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair · Early Phase 1, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 166 studies in Papillomavirus Infections with a site in United States — 32 open to participants now, 60 under way, 5 of them phase 3. Papillomavirus Infections · United States.
Among the 166 studies in Papillomavirus Infections with a site in United States, this one is the 114th largest by planned enrollment of the 132 interventional ones that give a count, is one of 10 that started in 2025, is one of 7 in phase 1, reaches primary completion later than 15 of the 59 other live ones, and was the 153rd registered.
580 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.
Browse Papillomavirus Infections studies →32 of the 166 studies in Papillomavirus Infections with a site in United States are open now. Recruiting first, the newest first:
University of Maryland, Baltimore · Sites in United States
Ages 18+
Daré Bioscience, Inc. · Sites in United States
Ages 22–50 · Women only
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+ · Women only
Washington University School of Medicine · Sites in United States
Ages 25+ · Women only · Healthy volunteers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 87 Papillomavirus Infections studies recruiting now, 38 (44%) set no upper age limit and 44 (51%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 24 Years to 64 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
166 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 48 · Phase 3 18 · Phase 4 8
First in 2003; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 229 across 404 interventional studies indexed under Papillomavirus Infections.
Median enrollment 128 across the 132 interventional studies, 197 across the 33 observational. Of the 95 that completed or were terminated, 47 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 166 have an industry lead sponsor. The 10 most frequent:
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair is the lead sponsor of 5 studies on the registry; none are open to participants now.
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair has 1 study filed under Papillomavirus Infections — fewer than ten, so there is no comparison to draw.
29 of the studies in Papillomavirus Infections with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07217145Phase 3University of UtahPREVENT HPV -Related Cancers Trial | 2026-11 |
| NCT04199689Phase 3Merck Sharp & Dohme LLCEfficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) | 2027-01-15 |
| NCT04965792Dana-Farber Cancer InstitutePost-treatment Surveillance in HPV+ Oropharyngeal SCC | 2026-11 |
| NCT04206813Boston Medical CenterAn Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen | 2026-12 |
| NCT05677360H. Lee Moffitt Cancer Center and Research InstituteHPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS) | 2026-12 |
Add all 29 to your calendar (.ics) → With an account.
Among the 166 studies in Papillomavirus Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix that suggests the potential for clinical benefit of HPV patients.
20 Cervical HPV Infection Patients
Inclusion Criteria:
Exclusion Criteria:
Therapeutic Biological Product Mix activity 9vHPV Vaccine 1.0 mL add into BCG Organism 50 MG
Biological: 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use
By the percutaneous route with the multiple puncture device - 9vHPV Vaccine 1.0 mL plus BCG Organism 50 MG Mix
Also known as: 9vHPV Vaccine plus BCG Organism Mix
20 HPV Participants with HPV testing by standard PCR assay
Negative testing HPV by standard PCR assay after percutaneous 21 days
Time frame: Duration at least 28 days
20 HPV Participants with IGRA blood test with HPV protein antigen
Positive IGRA blood test with HPV protein antigen after percutaneous use 21 days
Time frame: Duration at least 28 days
20 HPV Participants with IGRA blood test with TB antigens
* Negative IGRA blood test with TB antigens before percutaneous use * Positive IGRA blood test with TB antigens after percutaneous use 21 days
Time frame: Duration at least 28 days
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Apr 2025 (actual). Primary completion is estimated for Oct 2026, 17 months after the start.
Of 16 phase 1 interventional studies under Papillomavirus Infections, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 25. This study's planned 17 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair